drugset
drugset / Trial / NCT00029328

Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation

NCT00029328 ↗

Phase 1/2 Completed 15 enrolled FDA Office of Orphan Products Development
Non-randomizedOpen-labelTreatment

Summary

The purpose of this study is to determine the effects of etanercept, and define the toxicity, when administered to patients with acute non-infectious lung injury (idiopathic pneumonia syndrome, IPS) and with subacute pulmonary dysfunction after allogeneic stem cell transplantation.

Timeline

Start
2001-09
Primary completion
—
Completion
2003-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic — Subcutaneous

Indications

adult acute respiratory distress syndrome pneumonia transplant-related bronchiolitis obliterans